Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis

British Journal of Psychiatry

Volumn 209, Issue 5, 2016, Pages 385-392

  Siskind, Dan ^a,b   McCartney, Lara ^c   Goldschlager, Romi ^d   Kisely, Steve ^a,b,e  

^a Metro South Addiction and Mental Health Service   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

COMPARATIVE EFFECTIVENESS; CONSTIPATION; DIZZINESS; FEVER; HEADACHE; HUMAN; HYPERSALIVATION; HYPOTENSION; INSOMNIA; META ANALYSIS; NAUSEA; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; COMPARATIVE STUDY;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA;

EID: 84996527407     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.115177261     Document Type: Review

References (67)

1. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol 1977; 11: 193-8.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
3. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-62.
4. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia,second edition. Am J Psychiatry 2004; 161 (suppl 2): 1-56.
5. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management. CG 178. NICE, 2014.
6. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry 2005; 39: 1-30.
7. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14: 102.
8. Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S. Increasing clozapine dispensing trends in Queensland, Australia 2004-2013 Pharmacopsychiatry 2015; 48: 164-9.
9. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-5.
10. Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatmentresistant schizophrenia: a re-examination. Br J Psychiatry 2003; 183: 161-6.
11. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 2012; 1: 2.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA group (2009) preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
13. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255-62.
14. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41: 1397-402.
15. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990-9.
16. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration, 2011.
19. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, 1984.
20. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, 1983.
21. Leucht S, Rothe P, Davis JM, Engel RR. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol 2013; 23: 956-9.
22. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001; 158: 1305-13.
23. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 173-80.
24. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998; 155: 499-504.
25. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155: 751-60.
26. Cao HJ, You HF, Fan FL, Zhang J. The control study of risperidone and clozapine for the treatment-resistant schizophrenia. J Chinese Med Res 2003; 4: 316-9.
27. Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatmentrefractory schizophrenia. Int Clin Psychopharmacol 1997; 12: 123-30.
28. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001; 58: 965-72.
29. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53: 1090-7.
30. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, Thomas C, Kafantaris V, et al. Clozapine and 'high-dose' olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63: 524-9.
31. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-10.
32. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008; 69: 274-85.
33. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, et al. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol 2004; 18: 355-65.
34. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005; 111: 106-15.
35. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-15.
36. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009; 110: 80-9.
37. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapineolanzapine comparison. Arch Gen Psychiatry 2006; 63: 721-30.
38. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001; 49: 52-63.
39. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-62
40. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 911-22.
41. Wang RZ, Geng YY, Pan DH, Zhang SJ. A comparative trial of efficacy of risperidone vs clozapine in treatment of refractory schizophrenia. Chinese J Pharmacoepidemiol 2002; 5: 230-1.
42. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60.
43. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-70.
44. Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust NZ J Psychiatry 2012; 46: 816-25.
45. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55 (suppl B): 133-6.
46. Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013; 67: 407-11.
47. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010;36: 48-70.
48. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001, Aug;158(8):1305-13.
49. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004, Jan;28(1):173-80.
50. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. The risperidone study group. Am J Psychiatry 1998, Apr;155(4):499-504.
51. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998(6):751-60.
52. Cao HJ, You HF, Fan FL, Zhang J. The control study of risperidone and clozapine for the treatment-resistant schizophrenia 2003(4):316-9
53. Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on chinese patients with treatment-refractory schizophrenia 1997(3):123-30
54. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: A 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001, Oct;58(10):965-72.
55. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996, Dec;53(12):1090-7.
56. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, Thomas C, Kafantaris V, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison 2008(5):524-9
57. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, Apr;163(4):600-10.
58. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 2008, Feb;69 (2):274-85.
59. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, et al. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol 2004, Sep;18(3):355-65.
60. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, et al. Randomized double blind comparison of olanzapine vs. Clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005, Feb;111(2):106-15.
61. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997, Sep 18;337 (12):809-15.
62. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L, INITIATE Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophr Res 2009, May;110(1-3):80-9.
63. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, et al.Childhood-onset schizophrenia: A double-blind, randomized clozapineolanzapine comparison. Arch Gen Psychiatry 2006;63(7):721-30.
64. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001, Jan 1;49(1):52-63.
65. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder 2002(2):255-62
66. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2000;24(6):911-22.
67. Wang RZ, Geng YY, Pan DH, Zhang SJ. A comparative trial of efficacy of risperidone vs clozapine in treatment of refractory schizophrenia. Chinese Journal of Pharmacoepidemiology 2002(5):230-1.